Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3724-3733

  Ge, Qing ^a   Pastey, Manoj ^b   Kobasa, Darwyn ^c   Puthavathana, Piliapan ^d   Lupfer, Christopher ^b   Bestwick, Richard K ^e   Iversen, Patrick L ^e   Chen, Jianzhu ^a   Stein, David A ^e  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d MAHIDOL UNIVERSITY   (Thailand)

^e AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE RICH PEPTIDE; COMPLEMENTARY RNA; GENOMIC RNA; MORPHOLINE DERIVATIVE; NUCLEIC ACID; NUCLEOPROTEIN; OLIGOMER; PEPTIDE; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BASE PAIRING; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; GENE EXPRESSION; INFLUENZA VIRUS A; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA SEQUENCE; RNA TRANSLATION; SEQUENCE ANALYSIS; START CODON; STRAIN DIFFERENCE; TRANSLATION INITIATION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HEMAGGLUTINATION TESTS; HUMANS; INFLUENZA A VIRUS; MORPHOLINES; PLAQUE ASSAY; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; RNA, VIRAL; VERO CELLS;

EID: 33750592240     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00644-06     Document Type: Article

References (49)

1. Alonso, M., D. A. Stein, E. Thomann, H. M. Moulton, J. C. Leong, P. Iversen, and D. V. Mourich. 2005. Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers. J. Fish Dis. 28:399-410.
2. Anonymous. 2005. Antiviral drugs for prophylaxis and treatment of influenza. Med. Lett. Drugs Ther. 47:93-95.
3. Beigel, J. H., J. Farrar, A. M. Han, F. G. Hayden, R. Hyer, M. D. de Jong, S. Lochindarat, T. K. Nguyen, T. H. Nguyen, T. H. Tran, A. Nicoll, S. Touch, and K. Y. Yuen. 2005. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353:1374-1385.
4. Chen, W., P. A. Calvo, D. Malide, J. Gibbs, U. Schubert, I. Bacik, S. Basta, R. O'Neill, J. Schickli, P. Palese, P. Henklein, J. R. Bennink, and J. W. Yewdell. 2001. A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 7:1306-1312.
5. Choi, J. M., M. H. Ahn, W. J. Chae, Y. G. Jung, J. C. Park, H. M. Song, Y. E. Kim, J. A. Shin, C. S. Park, J. W. Park, T. K. Park, J. H. Lee, B. F. Seo, K. D. Kim, E. S. Kim, D. H. Lee, and S. K. Lee. 2006. Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat. Med. 12:574-579.
6. Cox, N. J., and K. Subbarao. 2000. Global epidemiology of influenza: past and present. Annu. Rev. Med. 51:407-421.
7. Crow, M., T. Deng, M. Addley, and G. G. Brownlee. 2004. Mutational analysis of the influenza virus cRNA promoter and identification of nucleotides critical for replication. J. Virol. 78:6263-6270.
8. Deas, T. S., I. Binduga-Gajewska, M. Tilguer, P. Ren, D. A. Stein, H. M. Moulton, P. L. Iversen, E. B. Kauffman, L. D. Kramer, and P. Y. Shi. 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79:4599-4609.
9. Enterlein, S., K. L. Warfield, D. L. Swenson, D. A. Stein, J. L. Smith, C. S.; Gamble, A. D. Kroeker, P. L. Iversen, S. Bavari, and E. Muhlberger. 2006. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 50:984-993.
10. Ge, Q., H. N. Eisen, and J. Chen. 2004. Use of siRNAs to prevent and treat influenza virus infection. Virus Res. 102:37-42.
11. Ge, Q., L. Filip, A. Bai, T. Nguyen, H. N. Eisen, and J. Chen. 2004. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 101:8676-8681.
12. Ge, Q., M. T. McManus, T. Nguyen, C. H. Shen, P. A. Sharp, H. N. Eisen, and J. Chen. 2003. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. USA 100:2718-2723.
13. Ghosh, C., D. Stein, D. Weller, and P. Iversen. 2000. Evaluation of antisense mechanisms of action. Methods Enzymol. 313:135-143.
14. Hayden, F. G., and A. J. Hay. 1992. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176:119-130.
15. Holden, K. L., D. A. Stein, T. C. Pierson, A. A. Ahmed, K. Clyde, P. L. Iversen, and E. Harris. 2006. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3′ stem-loop structure. Virology 344:439-452.
16. Horimoto, T., and Y. Kawaoka. 2001. Pandemic threat posed by avian influenza A viruses. Clin. Microbiol. Rev. 14:129-149.
17. Kinney, R. M., C. Y. Huang, B. C. Rose, A. D. Kroeker, T. W. Dreher, P. L. Iversen, and D. A. Stein. 2005. Inhibition of dengue viras serotypes 1 to 4 in Vero cell cultures with morpholino oligomers. J. Virol. 79:5116-5128.
18. Kiso, M., K. Mitamura, Y. Sakai-Tagawa, K. Shiraishi, C. Kawakami, K. Kimura, F. G. Hayden, N. Sugaya, and Y. Kawaoka. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765.
19. Lamb, R. A., and R. M. Krug. 2001. Orthomyxoviridae, p. 725-770. In D. M. Knipe and P. M. Howley (ed.), Fundamental virology. Lippincott, Williams, and Wilkins, Philadelphia, Pa.
20. Lamb, R. A., and R. M. Krug. 2001. Orthomyxoviridae: the viruses and their replication, chapter 46. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott, Williams, and Wilkins, Philadelphia, Pa.
21. Le, Q. M., M. Kiso, K. Someya, Y. T. Sakai, T. H. Nguyen, K. H. Nguyen, N. D. Pham, H. H. Ngyen, S. Yamada, Y. Muramoto, T. Horimoto, A. Takada, H. Goto, T. Suzuki, Y. Suzuki, and Y. Kawaoka. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
22. Lipatov, A. S., E. A. Govorkova, R. J. Webby, H. Ozaki, M. Peiris, Y. Guan, L. Poon, and R. G. Webster. 2004. Influenza: emergence and control. J. Virol. 78:8951-5959.
23. Ludwig, S., O. Planz, S. Pleschka, and T. Wolff. 2003. Influenza-virus-induced signaling cascades: targets for antiviral therapy? Trends Mol. Med. 9:46-52.
24. Macken, C., H. Lu, J. Goodman, and L. Boykin. 2001. The value of a database in surveillance and vaccine selection, p. 103-106. In A. D. M. E. Osterhaus, N. Cox, and A. W. Hampson (ed.), Options for the control of influenza. Elsevier Science, Amsterdam, The Netherlands.
25. McKimm-Breschkin, J. L. 2000. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antivir. Res. 47:1-17.
26. Mizuta, T., M. Fujiwara, T. Abe, N. Miyano-Kurosaki, T. Yokota, S. Shigeta, and H. Takaku. 2000. Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus. Biochem. Biophys. Res. Commun. 279:158-161.
27. Mizuta, T., M. Fujiwara, T. Hatta, T. Abe, N. Miyano-Kurosaki, S. Shigeta, T. Yokota, and H. Takaku. 1999. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Nat. Biotechnol. 17:583-587.
28. Moscona, A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-1373.
29. Moulton, H. M., M. H. Nelson, S. A. Hatlevig, M. T. Reddy, and P. L. Iversen. 2004. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug. Chem. 15:290-299.
30. Nagahara, H., A. M. Vocero-Akbani, E. L. Snyder, A. Ho, D. G. Latham, N. A. Lissy, M. Becker-Hapak, S. A. Ezhevsky, and S. F. Dowdy. 1998. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4:1449-1452.
31. Nelson, M. H., D. A. Stein, A. D. Kroeker, S. A. Hatlevig, P. L. Iversen, and H. M. Moulton. 2005. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity. Bioconjug. Chem. 16:959-966.
32. Neuman, B. W., D. A. Stein, A. D. Kroeker, M. J. Churchill, A. M. Kim, P. Kuhn, P. Dawson, H. M. Moulton, R. K. Bestwick, P. L. Iversen, and M. J. Buchmeier. 2005. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol. 79:9665-9676.
33. Neuman, B. W., D. A. Stein, A. D. Kroeker, A. D. Pauline, H. M. Moulton, P. L. Iversen, and M. J. Buchmeier. 2004. Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth. J. Virol. 78:5891-5899.
34. Palese, P. 2004. Influenza: old and new threats. Nat. Med. 10:S82-S87.
35. Park, Y. W., and M. G. Katze. 1995. Translational control by influenza virus. Identification of cis-acting sequences and trans-acting factors which may regulate selective viral mRNA translation. J. Biol. Chem. 270:28433-28439.
36. Portela, A., and P. Digard. 2002. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J. Gen. Virol. 83:723-734.
37. Portela, A., T. Zurcher, A. Nieto, and J. Ortin. 1999. Replication of orthomyxoviruses. Adv. Virus Res. 54:319-348.
38. Puthavathana, P., P. Auewarakul, P. C. Charoenying, K. Sangsiriwut, P. Pooruk, K. Boonnak, R. Khanyok, P. Thawachsupa, R. Kijphati, and P. Sawanpanyalert. 2005. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J. Gen. Virol. 86:423-433.
39. Schwarze, S. R., A. Ho, A. Vocero-Akbani, and S. F. Dowdy. 1999. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569-1572.
40. Stein, D., E. Foster, S. B. Huang, D. Weller, and J. Summerton. 1997. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7:151-157.
41. Stein, D. A., D. E. Skilling, P. L. Iversen, and A. W. Smith. 2001. Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 11:317-325.
42. Stiver, G. 2003. The treatment of influenza with antiviral drugs. Can. Med. Assoc. J. 168:49-56.
43. Summerton, J. 1999. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489:141-158.
44. Summerton, J., and D. Weller. 1997. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7:187-195.
45. Tado, M., T. Abe, T. Hatta, M. Ishikawa, S. Nakada, T. Yokota, and H. Takaku. 2001. Inhibitory effect of modified 5′-capped short RNA fragments on influenza virus RNA polymerase gene expression. Antivir. Chem. Chemother. 12:353-358.
46. Takahashi, H., H. Hamazaki, Y. Habn, M. Hayasbi, T. Abe, N. Miyano-Kurosaki, and H. Takaku. 2004. A new modified DNA enzyme that targets influenza virus A mRNA inhibits viral infection in cultured cells. FEBS Lett. 560:69-74.
47. Tompkins, S. M., C. Y. Lo, T. M. Tumpey, and S. L. Epstein. 2004. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101:8682-8686.
48. van den Born, E., D. A. Stein, P. L. Iversen, and E. J. Snijder. 2005. Antiviral activity of morpholino oligomers designed to block various aspects of equine arteritis virus amplification in cell culture. J. Gen. Virol. 86:3081-3090.
49. Zheng, H., P. Palese, and A. Garcia-Sastre. 1996. Nonconserved nucleotides at the 3′ and 5′ ends of an influenza A virus RNA play an important role in viral RNA replication. Virology 217:242-251.